Analysis of genotype and PIVKA-II level of Patients with HBV-related hepatocellular carcinoma in Kunming

doi:10.3877/cma.j.issn.2095-5820.2020.03.008

Abstract

Abstract:

Objective

To explore the clinical significance of genotype and PIVKA-II level of patients with HBV-related hepatocellular carcinoma in Kunming.

Methods

The HBV genotype and serum levels of PIVKA-II in 341 patients from the Third People′s Hospital of Kunming from November 2015 to November 2017 were detected by Sanger sequencing method and automatic immunoanalyzer respectively.

Results

The serum levels of PIVKA-II in HCC patients were significantly higher than those in liver cirrhosis group and chronic hepatitis B group (P<0.01). And with the increase of TNM tumor stage, the level of PIVKA-Ⅱ increased. The proportion of genotype C was higher than that of genotype B in HCC group, liver cirrhosis group and chronic hepatitis B group. However, there was no significant difference in the distribution of genotypes among the three groups (P>0.05). Also there was no significant difference in the distribution of hepatitis B genotypes in different TNM tumor stages (P>0.05).

Conclusions

PIVKA-II has high clinical value in the early diagnosis, treatment follow-up and prognostic assessment of HCC. Patients with genotype B cannot be ignored but should be paid attention to in the early diagnosis, treatment and efficacy monitoring of the HBV-related hepatocellular carcinoma.

Key words: HBV-related hepatocellular carcinoma, Genotype, Protein induced by vitamin K absence or antagonist-II

Tingting Yu, Dong Pu, Dongling Li, Hongying Wang, Runwu Zhang, Caimei Ding, Lihua Li, jing Bai, Xiaofei Li. Analysis of genotype and PIVKA-II level of Patients with HBV-related hepatocellular carcinoma in Kunming[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2020, 08(03): 166-169.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2020.03.008

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2020/V08/I03/166

Figures/Tables 4

References 16

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[2]	吴忱思，赵乐，吴建华, 等. 乙型肝炎病毒S区基因突变对乙型肝炎病毒相关性肝细胞癌患者预后的影响研究[J]. 中国全科医学, 2019,22(15):1807-1811.
[3]	TrPo C, Chan HLY, Lok A. Hepatitis B virus infection[J]. Lancet, 2014,384(9959):2053-2063.
[4]	Pollicino T, Cacciola I, Saffioti F, et al. Hepatitis B virus preS/S gene variants:pathobiology and clinical implications[J]. J Hepatol, 2014, 61(2):408-417.
[5]	Lu F M, Zhuang H. Management of hepatitis B in China[J]. Chin Med J, 2009,122(1):3-4.
[6]	郝华，杨俊英，侯临平, 等. 乙型肝炎病毒基因分型研究新进展[J].中国实用医刊, 2016,43(16):125-128.
[7]	林晓渊. 异常凝血酶蛋白在HBV相关肝癌中的诊断价值研究[J].中国社区医师, 2016,32(34):134-135.
[8]	王贵强，王福生，成军, 等. 慢性乙型肝炎防治指南(2015年版)[J]. 中华实验和临床感染病杂志(电子版), 2015,9(5):570-589.
[9]	黎晓武，李金强，罗向波, 等. 血清GP73、HSP27联合AFP检测在HBV相关早期肝细胞癌诊断的价值[J].实用预防医学, 2016, 21(11):1319-1321.
[10]	Hao X, Cunling Y, Liming C, et al. Clinical application of protein induced by vitamin K antagonist-H as a biomarker in hepatocellular caicinoma[J].Tumor biology, 2016,37(12):15447-15456.
[11]	Bertino G, Ardiri A, Malaguarnera MA, et al. Hepatocellular carcinoma serummarkers[J]. Semin Oncol, 2012,39(4):410-433.
[12]	吴朝，王可，王贵强, 等. 维生素K缺乏或拮抗剂Ⅱ诱导的蛋白质在原发性肝细胞癌临床诊断中的应用[J].国际流行病学传染病学杂志, 2016,43(4):217-221.
[13]	普冬，余婷婷，王红英, 等. 昆明地区乙型肝炎患者基因型和耐药情况分析[J].昆明医科大学学报, 2019,40(11):131-135.
[14]	张爱民，王慧芬，王海滨, 等. 中国30个地区HBV基因型分布特点和临床意义[J].中华实验和临床病毒学杂志, 2011,25(4):126-128.
[15]	CarmanWF, JacynaMR, HadziyannisS, et al. Mutation preventing formation of hepatitis B e antigen in the patients with chronic hepatitis B infection [J]. Lancet, 1989,2(8663):588-591.
[16]	孙明辉，刘龙，杨瑞萍, 等. 异常凝血酶原联合甲胎蛋白检测在HBV相关肝细胞癌中的诊断价值[J]. 中国肝脏病杂志(电子版), 2018,10(4):7-12.

组别	例数	PIVKA-Ⅱ(mAU/mL)
乙肝相关肝细胞癌组	124	2324.00(46.00, 71500.00)
乙肝相关肝硬化组	100	24.00(10.25, 42.00)*
慢乙肝组	117	26.00(24.00, 39.50)*

组别	例数	PIVKA-Ⅱ(mAU/mL)
乙肝相关肝细胞癌组	124	2324.00(46.00, 71500.00)
乙肝相关肝硬化组	100	24.00(10.25, 42.00)*
慢乙肝组	117	26.00(24.00, 39.50)*

组别	基因型分布[n(%)]		χ²	P
组别	B型	C型	χ²	P
乙肝相关肝细胞癌组	51(41.1%)	73(58.9%)	0.179	>0.05
乙肝相关肝硬化组	42(42.0%)	58(58.0%)
慢乙肝组	45(38.4%)	72(61.6%)

组别	基因型分布[n(%)]		χ²	P
组别	B型	C型	χ²	P
乙肝相关肝细胞癌组	51(41.1%)	73(58.9%)	0.179	>0.05
乙肝相关肝硬化组	42(42.0%)	58(58.0%)
慢乙肝组	45(38.4%)	72(61.6%)

TNM分期	例数	PIVKA-Ⅱ(mAU/mL)
Ⅰ期	54	70.52(46.25, 415.75)
Ⅱ期	47	1589.60(265.45, 2908.43)
Ⅲ期	15	24865.81(2024.35, 64839.75)
Ⅳ期	8	63591.87(6597.35, 71500.75)

Please choose a citation manager

Content to export